Nurix Therapeutics Ownership | Who Owns Nurix Therapeutics?


OverviewForecastRevenueFinancialsChart

Nurix Therapeutics Ownership Summary


Nurix Therapeutics is owned by 15.95% institutional investors, 1.13% insiders, and 82.93% retail investors. Blackrock is the largest institutional shareholder, holding 12.42% of NRIX shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 3.19% of its assets in Nurix Therapeutics shares.

NRIX Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockNurix Therapeutics15.95%1.13%82.93%
SectorHealthcare Stocks 232.63%10.66%-143.29%
IndustryBiotech Stocks 382.12%10.42%-292.54%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock6.82M12.42%$142.33M
Fmr8.89M10.56%$82.12M
Blackrock funding, inc. /de8.88M9.33%$168.36M
Deep track capital, lp6.06M7.20%$55.97M
Vanguard group5.95M6.26%$112.86M
Morgan stanley4.88M5.63%$92.59M
Baker bros. advisors lp3.88M4.61%$35.87M
Commodore capital lp3.78M4.49%$34.93M
Redmile group3.68M4.37%$33.99M
Vestal point capital, lp3.48M4.13%$32.11M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Redmile group3.68M3.31%$33.99M
Commodore capital lp3.78M1.71%$34.93M
Deep track capital, lp6.06M1.56%$55.97M
Kynam capital management, lp2.17M1.49%$20.04M
Vestal point capital, lp3.48M1.45%$32.11M
Rhenman & partners asset management ab537.50K0.95%$10.20M
Soleus capital management1.22M0.85%$23.13M
Westhill financial advisors228.33K0.82%$4.33M
Vienna powszechne towarzystwo emerytalne s.a. vienna insurance group85.00K0.79%$1.61M
Affinity asset advisors967.62K0.78%$8.94M

Top Buyers

HolderShares% AssetsChange
Morgan stanley4.88M0.01%2.62M
Rubric capital management lp2.47M0.56%2.47M
Blackrock6.82M0.00%2.24M
Blackrock funding, inc. /de8.88M0.00%2.11M
Pictet asset management sa3.47M0.06%1.49M

Top Sellers

HolderShares% AssetsChange
Price t rowe associates inc /md/1.10M0.00%-1.93M
Fmr8.89M0.00%-1.55M
Ra capital management---1.33M
T. rowe price investment management1.20M0.01%-1.28M
Wellington management group llp255.79K0.00%-1.21M

New Positions

HolderShares% AssetsChangeValue
Rubric capital management lp2.47M0.56%2.47M$46.93M
Norges bank318.80K0.00%318.80K$6.01M
Lighthouse investment partners50.00K0.01%50.00K$462.00K
Tudor investment corp et al37.94K0.00%37.94K$350.59K
Oxford asset management llp29.95K0.10%29.95K$276.76K

Sold Out

HolderChange
Twin peaks wealth advisors-1.00
True wealth design-4.00
Ifp advisors-6.00
Nelson, van denburg & campbell wealth management group-9.00
Federated hermes-15.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202539-77.59%15,163,987-82.11%150.16%26-68.67%7-88.14%
Sep 30, 202546-72.12%9,091,319-89.71%100.10%18-80.43%17-59.52%
Jun 30, 2025164-4.09%88,304,1285.07%1051.04%91-3.19%42-17.65%
Mar 31, 2025171-3.93%84,588,6764.29%1010.69%93-11.43%5110.87%
Dec 31, 20241771.72%81,111,27120.04%1201.40%1039.57%47-16.07%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv3.28M3.19%-19.27K
Vanguard US Total Market Shares ETF2.13M2.79%196.50K
iShares Russell 2000 ETF2.42M2.35%1.46M
Fidelity Select Health Care1.69M2.21%90.00K
Xtrackers MSCI World Swap ETF 1C2.14M2.08%-13.47K
Pictet-Biotech P USD1.95M1.90%497.57K
US Small-Cap Growth II Equity Comp1.35M1.76%14.21K
ARK Genomic Revolution ETF1.57M1.53%-
State Street® SPDR® S&P® Biotech ETF1.55M1.51%-8.36K
ARK Genomic Revolution1.53M1.49%68.92K

Recent Insider Transactions


DateNameRoleActivityValue
Mar 02, 2026Ring Christine Chief Legal OfficerSell$125.79K
Feb 09, 2026Ring Christine Chief Legal OfficerSell$237.62K
Jan 30, 2026van Houte Hans Chief Financial OfficerSell$1.27K
Jan 30, 2026van Houte Hans Chief Financial OfficerSell$59.50K
Jan 30, 2026Ring Christine Chief Legal OfficerSell$71.85K

Insider Transactions Trends


DateBuySell
2026 Q1-9
2025 Q4-7
2025 Q3-4
2025 Q2-4
2025 Q1-11

NRIX Ownership FAQ


Who Owns Nurix Therapeutics?

Nurix Therapeutics shareholders are primarily institutional investors at 15.95%, followed by 1.13% insiders and 82.92% retail investors. The average institutional ownership in Nurix Therapeutics's industry, Biotech Stocks , is 382.12%, which Nurix Therapeutics falls below.

Who owns the most shares of Nurix Therapeutics?

Nurix Therapeutics’s largest shareholders are Blackrock (6.82M shares, 12.42%), Fmr (8.89M shares, 10.56%), and Blackrock funding, inc. /de (8.88M shares, 9.33%). Together, they hold 32.32% of Nurix Therapeutics’s total shares outstanding.

Does Blackrock own Nurix Therapeutics?

Yes, BlackRock owns 12.42% of Nurix Therapeutics, totaling 6.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 142.33M$. In the last quarter, BlackRock increased its holdings by 2.24M shares, a 48.90% change.

Who is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested?

Redmile group is Nurix Therapeutics’s biggest shareholder by percentage of total assets invested, with 3.31% of its assets in 3.68M Nurix Therapeutics shares, valued at 33.99M$.

Who is the top mutual fund holder of Nurix Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Nurix Therapeutics shares, with 3.19% of its total shares outstanding invested in 3.28M Nurix Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools